Everolimus

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Everolimus

Examples of brand names: Certican [DE]; Afinitor [EU/DE]

ATC code: L04AH02

Main use (for orientation): Transplantation; oncology

Documented research summary

CBD–everolimus directly supported by a phase I study: AUC/Cmax approximately 2.5-fold with CBD 12.5 mg/kg twice daily. Additional TSC cases/series show increased trough concentrations; therapeutic drug monitoring rather than blanket dose reduction.

Uncertainties and limitations

Do not extrapolate the pharmacokinetic magnitude to every CBD oil type, dose or transplantation setting. Abstract 31539915 contains a unit typo, 20.4 g/kg; not adopted.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – clinically studied

Finding ID: B0020

Type of result: Positive finding / indication

Observation: Cmax geometric mean ratio 2.50 (90% CI 2.12–2.94), AUC0–last ratio 2.55 (2.23–2.90), AUC0–∞ ratio 2.45 (2.15–2.80); mean half-life 40.0→33.2 hours.

Mechanism: Increased bioavailability; intestinal P-gp suspected

Study type: Open-label phase I pharmacokinetics

Context studied: n=16; CBD 12.5 mg/kg twice daily; everolimus 5 mg.

Clinical interpretation: High

Limitations and uncertainties: P-gp not directly measured in isolation; long-term patient data absent.

Original sources for this finding: Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial [CL08]

CBD – clinical signals

Finding ID: B0080

Type of result: Positive finding / indication

Observation: Median trough-concentration increase +9.8 ng/ml.

Mechanism: Mechanism not established

Study type: Retrospective case series

Context studied: 25 TSC patients in total: 18 receiving everolimus and 7 receiving sirolimus.

Clinical interpretation: Potentially high

Limitations and uncertainties: Uncontrolled retrospective series; n=18 receiving everolimus, not an overall sample independent of the sirolimus series.

Original sources for this finding: Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex [CL23]

References and access status

[CA_L_D0022] ZORTRESS (EVEROLIMUS) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION]

Original source / bibliographic reference

Authors: Novartis Pharmaceuticals Corporation

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL08] Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial

Original source / bibliographic reference

Authors: Wray L; Berwaerts J; Critchley D; Hyland K; Chen C; Thai C; Tayo B

Year: 2023

Source type: Open-label phase I study, fixed sequence

DOI: 10.1002/cpdd.1262

PMID: 37132402

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CL23] Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex

Original source / bibliographic reference

Authors: Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN

Year: 2020

Source type: Retrospective case series

DOI: 10.1016/j.pediatrneurol.2019.11.017

PMID: 31924480

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_31539915] Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex.

Original source / bibliographic reference

Authors: Wiemer-Kruel A, Stiller B, Bast T.

Year: 2019

Source type: Journal Article; Case Reports

DOI: 10.1055/s-0039-1695786

PMID: 31539915

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_PMC7715614] DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE

Original source / bibliographic reference

Authors: Sabus A, Winzent S, Hemenway M, Levy J, Foreman N.

Year: 2020

Source type: Abstract

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed Central – archived text

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility